OmniAb (OABI) Amortizatization of Intangibles (2022 - 2026)
OmniAb (OABI) reported Amortizatization of Intangibles of $6.0 million for Q1 2026, up 85.87% year-over-year from $3.2 million in Q1 2025, and up 2359.02% on a QoQ basis from $244000.0 in Q4 2025.
OmniAb (OABI) has 5 years of Amortizatization of Intangibles data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 85.87% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 11.55% YoY) and the FY2025 annual result came in at $858000.0, down 42.72% from the prior year.
- Amortizatization of Intangibles climbed to $6.0 million in Q1 2026 per OABI's latest filing, from $244000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $6.0 million in Q1 2026 and bottomed at -$2.8 million in Q2 2025.
- The 5-year median for Amortizatization of Intangibles is $499500.0 (2024), against an average of $854785.7.
- Peak annual rise in Amortizatization of Intangibles reached 418.97% in 2025, while the deepest fall reached 838.99% in 2025.
- Tracing OABI's Amortizatization of Intangibles over 5 years: stood at $170000.0 in 2022, then jumped by 364.71% to $790000.0 in 2023, then plunged by 73.04% to $213000.0 in 2024, then gained by 14.55% to $244000.0 in 2025, then soared by 2359.02% to $6.0 million in 2026.
- Per Business Quant, the three latest OABI Amortizatization of Intangibles figures stand at $6.0 million (Q1 2026), $244000.0 (Q4 2025), and $172000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.00 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 244,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Jun 30, 2025 | -2.79 Mn |
| Jun 30, 2025 | -2.79 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 213,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 622,000.00 |
| Mar 31, 2024 | 622,000.00 |
| Dec 31, 2023 | 790,000.00 |
| Dec 31, 2023 | 790,000.00 |
| Sep 30, 2023 | 828,000.00 |
| Sep 30, 2023 | 828,000.00 |
| Jun 30, 2023 | 890,000.00 |
| Jun 30, 2023 | 890,000.00 |
| Mar 31, 2023 | 933,000.00 |
| Mar 31, 2023 | 933,000.00 |
| Dec 31, 2022 | 170,000.00 |
| Dec 31, 2022 | 170,000.00 |